Ionis Pharmaceuticals, Inc.
IONS · NASDAQ-GS
IONS · NASDAQ-GS
The supplied evidence identifies Ionis Pharmaceuticals as a publicly traded pharmaceutical company but does not describe its medicines, therapeutic areas, commercial segments, royalty arrangements, collaboration economics, or customer base. The available financial figures show FY2025 revenue of $0.9 billion and a net loss of $0.4 billion, compared with FY2024 revenue of $0.7 billion and a net loss of $0.5 billion. Consequently, the evidence supports describing Ionis as a company with substantial annual revenue and continuing losses, but not its product mix, revenue contribution by segment, operating scale beyond those figures, or the identity of its customers.
